X0306 4 2020-04-20 0 0000879407 ARROWHEAD PHARMACEUTICALS, INC. ARWR 0001219384 GIVEN BRUCE D 177 E. COLORADO BLVD SUITE 700 PASADENA CA 91105 0 1 0 0 Chief Operating Officer Common Stock 2020-04-20 4 M 0 3800 4.75 A 862793 D Common Stock 2020-04-20 4 M 0 3700 5.19 A 866493 D Common Stock 2020-04-20 4 M 0 3456 5.20 A 869949 D Common Stock 2020-04-20 4 M 0 5300 14.54 A 875249 D Common Stock 2020-04-20 4 S 0 3800 40.00 D 871449 D Common Stock 2020-04-20 4 S 0 3700 40.00 D 867749 D Common Stock 2020-04-20 4 S 0 3456 40.00 D 864293 D Common Stock 2020-04-20 4 S 0 5300 40.00 D 858993 D Common Stock 2020-04-20 4 S 0 3454 40.00 D 855539 D Common Stock 2020-04-20 4 S 0 3805 40.00 D 851734 D Stock Option (right to buy) 4.75 2020-04-20 4 M 0 3800 0.00 D 2013-10-01 2023-09-21 Common Stock 3800 346200 D Stock Option (right to buy) 5.19 2020-04-20 4 M 0 3700 0.00 D 2012-03-01 2022-02-16 Common Stock 3700 342500 D Stock Option (right to buy) 5.20 2020-04-20 4 M 0 3456 0.00 D 2012-04-01 2021-10-26 Common Stock 3456 339044 D Stock Option (right to buy) 14.54 2020-04-20 4 M 0 5300 0.00 D 2014-03-01 2024-02-06 Common Stock 5300 333744 D Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4 Represents first vesting date. Option vested over four years from date of grant. /S/ Bruce Given 2020-04-22